Cancer Epigenetics and Nuclear Dynamics (CEND) Research Program

癌症表观遗传学与核动力学 癌症表观遗传学与核动力学(CEND)是美国罗伯特·霍普金斯大学的一项新的基础科学研究计划。 基础科学项目重组后出现的Lurie综合癌症中心 在2015年。CEND计划的目标是了解核心是如何结构组织和 与未转化细胞相比，在癌细胞中具有功能调节，并加速BASIC的翻译 癌症表观遗传学和基因调控方面的发现，以开发新的治疗和诊断应用。 凭借这一重点，CEND汇集了前癌细胞生物学和信号转导研究所的教员 计划外加六个新的LCC成员。这些教员拥有广泛的专业知识，他们使用不同的 模型系统，从酵母、果蝇和线虫到小鼠模型和原发人类恶性肿瘤 细胞。CEND的目的是：1.了解基因组组织在肿瘤发生和发展过程中的变化 组织变化是否有助于肿瘤进展。2.了解表观遗传调控 在肿瘤形成过程中的变化。3.了解非编码RNA如何影响肿瘤发生。4.了解 转录因子与癌症的关系。 该项目由文学院分子生物科学教授理查德·卡修博士领导。 德巴巴拉塔·查克拉瓦蒂博士，范伯格医学院药理学教授。 在最新一轮融资周期之前，两位领导人都曾在LCC担任过项目领导职位。CEND会员资格 由来自9个系和2个学院的29名教职员工组成。目前与癌症相关的同行评审的直接资助 8175,046美元，其中2,670,481美元来自NCI，5,504,565美元来自其他NIH研究所和同行审查 消息来源。自上次CCSG审查以来，已有375份与癌症相关的出版物。其中，17% 来自方案内协作的出版物中，39%来自方案间协作， 而则源于与其他癌症中心的合作。114(30%)是高影响力(&gt；9)出版物。 因此，CEND成员有效地在计划内外进行合作。CEND的另一个优先事项是 促进计划成员和临床/翻译研究人员之间的互动，以利用基础 开发新的治疗和诊断应用的发现。因此，CEND为 癌症中心通过提供概念更新和重点关注的框架来促进临床翻译 基本发现。

ABSTRACT – CANCER EPIGENETICS AND NUCLEAR DYNAMICS Cancer Epigenetics and Nuclear Dynamics (CEND) is a new basic science research program in the Robert H. Lurie Comprehensive Cancer Center (LCC) that emerged after the re-organization of the basic science programs in 2015. The goals of the CEND program are to understand how the nucleus is structurally organized and functionally regulated in cancer cells as compared to non-transformed cells, and to accelerate translation of basic discoveries in cancer epigenetics and gene regulation to develop new therapeutic and diagnostic applications. With this focus, CEND brings together faculty from the former Cancer Cell Biology and Signal Transduction Programs plus six new LCC members. These faculty have a broad range of expertise, and they use diverse model systems, ranging from yeast, Drosophila and C. elegans to mouse models and primary human malignant cells. The aims of CEND are to: 1. Understand how genome organization changes during tumorigenesis and whether organizational changes contribute to tumor progression. 2. Understand how epigenetic regulation changes during tumorigenesis. 3. Understand how non-coding RNAs affect tumorigenesis. 4. Understand the relationship between transcription factors and cancer. The Program is led by Richard Carthew, PhD, Professor of Molecular Biosciences at the College of Arts and Sciences and Debabrata Chakravarti, PhD, Professor of Pharmacology at the Feinberg School of Medicine. Both leaders have held program leadership positions in LCC prior to this latest funding cycle. CEND membership comprises 29 faculty from 9 departments and 2 schools. Current cancer-relevant peer-reviewed direct funding is $8,175,046, with $2,670,481 from NCI and $5,504,565 in funding from other NIH institutes and peer review sources. There have been 375 cancer-relevant publications since last competing CCSG review. Of these, 17% of publications arose from intra-programmatic collaborations, 39% arose from inter-programmatic collaborations, and 64% arose from collaborations with other cancer centers. 114 (30%) were high impact (>9) publications. Thus, CEND members effectively collaborate within and outside of the program. Another priority for CEND is to promote interactions between program members and clinical/translational researchers in order to harness basic discoveries to develop new therapeutic and diagnostic applications. CEND thus adds significant value to the cancer center by providing a conceptually renewed and focused framework for promoting clinical translation of basic discoveries.